JP2024535637A5 - - Google Patents
Info
- Publication number
- JP2024535637A5 JP2024535637A5 JP2024542231A JP2024542231A JP2024535637A5 JP 2024535637 A5 JP2024535637 A5 JP 2024535637A5 JP 2024542231 A JP2024542231 A JP 2024542231A JP 2024542231 A JP2024542231 A JP 2024542231A JP 2024535637 A5 JP2024535637 A5 JP 2024535637A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- chain variable
- variable region
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111139621 | 2021-09-27 | ||
| CN202111139621.4 | 2021-09-27 | ||
| CN202210915323.8 | 2022-08-01 | ||
| CN202210915323 | 2022-08-01 | ||
| PCT/CN2022/121776 WO2023046202A1 (zh) | 2021-09-27 | 2022-09-27 | 一种抗体及其药物偶联物和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535637A JP2024535637A (ja) | 2024-09-30 |
| JP2024535637A5 true JP2024535637A5 (enExample) | 2026-02-18 |
Family
ID=85720158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024542231A Pending JP2024535637A (ja) | 2021-09-27 | 2022-09-27 | 抗体及びその薬物コンジュゲ－ト並びに用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240409628A1 (enExample) |
| EP (1) | EP4410372A1 (enExample) |
| JP (1) | JP2024535637A (enExample) |
| KR (1) | KR20240082348A (enExample) |
| CN (1) | CN118159300A (enExample) |
| AU (1) | AU2022350588A1 (enExample) |
| CA (1) | CA3233254A1 (enExample) |
| WO (1) | WO2023046202A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024123914A1 (en) * | 2022-12-07 | 2024-06-13 | Merck Sharp & Dohme Llc | Process for making antibody-drug conjugates |
| CN121285392A (zh) * | 2023-05-09 | 2026-01-06 | 上海复宏汉霖生物技术股份有限公司 | 一种抗pdl1抗体-药物偶联物及应用 |
| KR20260007618A (ko) * | 2023-05-09 | 2026-01-14 | 상하이 헨리우스 바이오테크, 인크. | 항-표피 성장 인자 수용체(egfr) 항체-약물 접합체 및 이의 응용 |
| JP7689606B2 (ja) * | 2023-06-20 | 2025-06-06 | イーライ リリー アンド カンパニー | ネクチン－４抗体及び抗体－薬物コンジュゲート |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| CN120437319A (zh) * | 2024-02-07 | 2025-08-08 | 长春金赛药业有限责任公司 | 带有连接系统的抗体药物偶联物 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025248072A1 (en) * | 2024-05-30 | 2025-12-04 | BioNTech SE | Use of anti-her3 antibody-drug conjugates in cancer treatment |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026086850A1 (en) * | 2024-10-23 | 2026-04-30 | Zai Lab (Shanghai) Co., Ltd. | Dosing regimens of antibody-drug conjugate targeting delta-like ligand 3 for treatment of neuroendocrine neoplasms |
| WO2026085745A1 (en) * | 2024-10-23 | 2026-04-30 | Zai Lab (Shanghai) Co., Ltd. | Dosing regimens of antibody-drug conjugate targeting delta-like ligand 3 for treatment of neuroendocrine neoplasms |
| CN119345386B (zh) * | 2024-10-25 | 2025-12-09 | 华润生物医药有限公司 | 靶向Claudin18.2的抗体药物耦联物及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| BR112020020466A2 (pt) | 2018-04-06 | 2021-01-12 | Seattle Genetics, Inc. | Conjugados de peptídeo de camptotecina |
| TWI851577B (zh) * | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| CN111867630B (zh) * | 2018-06-17 | 2023-10-13 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| CN111110862A (zh) * | 2018-11-01 | 2020-05-08 | 上海健信生物医药科技有限公司 | 抗cldn18．2抗体的药物偶联体及其制备方法和用途 |
| EP3878863A4 (en) * | 2018-08-27 | 2022-06-22 | Nanjing Sanhome Pharmaceutical Co., Ltd. | ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE |
| KR20210083282A (ko) * | 2018-12-17 | 2021-07-06 | 레메젠 코, 리미티드 | 항체-약물 컨쥬게이트에 사용하기 위한 커넥터 및 커넥터의 적용 |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| JP7407841B2 (ja) * | 2019-05-16 | 2024-01-04 | 斉魯制薬有限公司 | クローディン１８ａ２に対する抗体及びその応用 |
| JP7407845B2 (ja) * | 2019-06-28 | 2024-01-04 | シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド | 抗体薬物複合体、その中間体、製造方法及び使用 |
| CN112237634B (zh) * | 2019-07-19 | 2023-11-28 | 上海复旦张江生物医药股份有限公司 | 抗体药物偶联物、其中间体、制备方法及应用 |
| CN119504997A (zh) | 2021-02-09 | 2025-02-25 | 苏州宜联生物医药有限公司 | 生物活性物偶联物及其制备方法和用途 |
-
2022
- 2022-09-27 CN CN202280065004.0A patent/CN118159300A/zh active Pending
- 2022-09-27 EP EP22872245.0A patent/EP4410372A1/en active Pending
- 2022-09-27 US US18/695,296 patent/US20240409628A1/en active Pending
- 2022-09-27 AU AU2022350588A patent/AU2022350588A1/en active Pending
- 2022-09-27 WO PCT/CN2022/121776 patent/WO2023046202A1/zh not_active Ceased
- 2022-09-27 JP JP2024542231A patent/JP2024535637A/ja active Pending
- 2022-09-27 CA CA3233254A patent/CA3233254A1/en active Pending
- 2022-09-27 KR KR1020247011648A patent/KR20240082348A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240409628A1 (en) | Antibody, antibody-drug conjugate thereof and use thereof | |
| AU2016232839B2 (en) | CD48 antibodies and conjugates thereof | |
| EP3134125B1 (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| ES2884844T3 (es) | Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3 | |
| CA3172720A1 (en) | Conjugates | |
| KR20160142392A (ko) | 튜부리신 유도체 | |
| JP2025508009A5 (enExample) | ||
| CA3113378C (en) | Sulfomaleimide-based linkers and corresponding conjugates | |
| JP2025508779A5 (enExample) | ||
| CN120813607A (zh) | 抗psma抗体、缀合物和使用方法 | |
| KR20250136340A (ko) | 링커 약물 및 이의 항체-약물 접합체의 제조 방법과 응용 | |
| US20260021194A1 (en) | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | |
| RU2815199C2 (ru) | Линкеры на основе сульфомалеимида и соответствующие конъюгаты | |
| JP2025168320A (ja) | タンパク質チロシンキナーゼ７抗体及び抗体－薬物コンジュゲート | |
| CN120957758A (zh) | 大环化合物及其制备方法和用途 | |
| RU2025119602A (ru) | Антитело к c-met, конъюгат антитело-лекарственный препарат, способ их получения и их применение | |
| HK1248538B (zh) | Cd48抗体和其缀合物 |